A 66-year-old man was referred to our hospital with obstructive jaundice. Computed tomography(CT)scan showed thickening of the gallbladder wall, invasion into the liver bed, and thickening of the rectal wall. Colonoscopy revealed a type 2 rectal cancer, in which adenocarcinoma was identified by endoscopic biopsy. He was diagnosed with double-cancer of the gallbladder and rectum. Because his gallbladder cancer was more life threatening than his rectal cancer, gemcitabine was administered at 1, 000 mg/m2 on days 1, 8, and 15 of a 28-day course. After 3 courses of gemcitabine, the CT scan showed that the lymph nodes in the hepatoduodenal ligament had been enlarged, and duodenal stenosis had occurred as a result of gallbladder cancer invasion. S-1 was administered orally at doses of 120 mg/day twice daily on days 1-28 of a 42-day course. Partial response was confirmed by CT scan. After 8 courses of S-1, the gallbladder cancer had progressed and liver metastases had appeared. He subsequently died of disease progression. He survived for 17 months after the first course of chemotherapy, and the progression-free survival with S-1 was 10 months. Therefore, S-1 could be an effective agent for synchronous double cancer of the gallbladder and rectum.
Download full-text PDF |
Source |
---|
J Gastrointest Surg
January 2025
Division of Surgical Oncology, Department of Surgery, Yale University School of Medicine, New Haven, CT. Electronic address:
Background: Despite efforts to expand insurance coverage, substantial inequalities persist, particularly in cancer treatment. We aimed to evaluate whether quality disparities exist across major insurance plans for patients undergoing curative-intent resection for gastrointestinal (GI) cancers.
Methods: This is a retrospective study of adult patients in the National Cancer Database (NCDB) diagnosed with GI malignant neoplasms between January 1, 2004 and December 31, 2020.
Arch Public Health
December 2024
Department of General Surgery, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, China.
Introduction: Gastrointestinal cancers encompass malignant tumors of multiple digestive system organs in humans. Each type of digestive system cancer also contains different histological types, each of which has a distinct prognosis. The survival time of cancer patients has significantly extended with the development of modern medicine, allowing for primary cancers occurring more than once in a lifetime.
View Article and Find Full Text PDFIndian J Community Med
June 2024
Department of Biostatistician, Hospital Based Cancer Registry, State Cancer Institute, IGIMS, Patna, Bihar, India.
World J Gastrointest Oncol
September 2024
Department of Primary Healthcare Management, Nanjing Municipal Center for Disease Control and Prevention, Nanjing 210003, Jiangsu Province, China.
Clin Epidemiol
September 2024
College of Public Health, Zhengzhou University, Gaoxin District, Zhengzhou, Henan, 450001, People's Republic of China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!